Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.

Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.

Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.